FDA Approved: MEPRON — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved GlaxoSmithKline's supplemental application for Mepron (atovaquone). It updates the drug's labeling and indications under NDA 020500.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumocystis Jirovecii Pneumonia

Drugs mentioned

• MEPRON (ATOVAQUONE)

Snippet

SUPPL AP for MEPRON (ATOVAQUONE)